Canopy Growth Corporation (CGC)

Over the past six months, Canopy Growth's stock (CGC) has shown significant volatility and a downward trend, with a share price of $1.19 as of November 25, 2025, a 69.80% decline over the past year. Key events include the Q2 Fiscal Year 2026 earnings release on November 7, 2025, where the company reported an EPS of -$0.01, beating estimates but missing revenue expectations. An annual general meeting was held on October 10, 2025. The company reported Q1 EPS of -$0.22 on August 8, 2025. Benchmark upgraded Canopy Growth to "Hold" from "Sell" in November 2025, citing improved liquidity and execution. A 1-for-10 reverse stock split occurred on December 20, 2023, impacting historical price comparisons.

Demand for Canopy Growth's products exhibits some seasonality. The third fiscal quarter, including the holiday selling season, is traditionally strong for its Storz & Bickel segment. "Green Wednesday" has emerged as the second-biggest day for cannabis sales in the U.S., indicating a holiday-driven surge in demand. The re-introduction of Wana edibles and investments in in-market activations are expected to strengthen the Canada adult-use cannabis business in the second half of fiscal year 2025. Ongoing demand in Germany, driven by active marketing campaigns, is also expected to contribute to growth in the European market.

Canopy Growth Corporation, based in Smiths Falls, Ontario, Canada, is a global cannabis and cannabinoid-based consumer product company. It focuses on producing, distributing, and selling cannabis and hemp-based products for recreational and medical use. The company operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. Canopy Growth offers a diverse product range under brands like Tweed, 7ACRES, DOJA, Tokyo Smoke, Spectrum Therapeutics, Martha Stewart CBD, and Storz & Bickel, including dried cannabis flower, pre-rolled joints, extracts, edibles, beverages, vapes, and wellness products.

Canopy Growth operates in Canada, the United States, and Europe, with involvement in Australia, Jamaica, Chile, Peru, and Brazil. In Canada, it runs retail stores under the Tweed and Tokyo Smoke brands in provinces allowing private cannabis sales. Internationally, Canopy Growth partners with Alcaliber S.A. in Spain, owns Spectrum Therapeutics GmbH in Germany for medical cannabis imports, and collaborates with Spectrum Cannabis Denmark ApS for cultivation. The company is also developing markets in Australia and South America using an asset-light model.

Canopy Growth's brand reputation has been influenced by its financial performance and strategic adjustments in a challenging market. The company has faced strong competition and financial challenges, with revenue decreasing in 2024. Recent financial results show positive signs, with the company narrowing its adjusted EBITDA loss and demonstrating momentum in medical cannabis and Storz & Bickel businesses. The acquisition of Wana Brands by Canopy USA is expected to drive brand integration and growth. The company is focused on optimizing operations for improved profitability and global reach, and its balance sheet is considered strong with low risk.

Canopy Growth is owned by a mix of institutional shareholders, insiders, and retail investors. Approximately 9.35% of the company is owned by institutional shareholders, 31.53% by Canopy Growth insiders, and 59.12% by retail investors. Greenstar II Holdings LLC is the largest individual shareholder, owning 104.50 million shares, representing 30.54% of the company. Major institutional owners include Amplify ETF Trust - Amplify Alternative Harvest ETF, Toroso Investments, LLC, Susquehanna International Group LLP, Citadel Advisors LLC, Millennium Management LLC, and D. E. Shaw & Co., Inc.. Insiders have recently bought more company stock than they have sold in the past three months.